Home » Newsletters » BioWorld Science

BioWorld Science

July 22, 2015

View Archived Issues

Symic Biomedical selects vascular clinical candidate SBCV-030

Evolocumab becomes first PCSK9 inhibitor approved in the world

FDA grants breakthrough therapy designation to BMS-663068

NEI starts phase I/II clinical study of AAV8-RS1 gene therapy for XLRS

OAT-449 shows in vitro efficacy as a microtubule-destabilizing compound

Verva Pharmaceuticals agrees to sell IP, appoints liquidator

Spero Therapeutics receives first milestone payment under Roche anti-infectives collaboration

JCR Pharmaceuticals and Eisai sign J-Brain Cargo feasibility agreement

Emergent BioSolutions awarded BARDA contract to develop and manufacture Ebola antibodies

New potential biomarkers for early-stage AD

Forge Therapeutics enters metalloprotein inhibitor pilot study with Janssen

Isis Pharmaceuticals begins phase I/IIa trial of ISIS-HTTRx in Huntington's disease

Panoptes' nonsteroidal drug presented for inflammatory eye diseases

Tekmira to change name, focus on HBV

Merck Patent discloses PARP-1 and/or TNKS-1 and/or TNKS-2 inhibitors

OncoTartis patents compounds for leukemia

Purdue Pharma reports kappa- and mu-opioid agonists

Cytox and Affymetrix partner to develop blood test for Alzheimer's disease risk

Shionogi develops P2X7 antagonists

Cephalon reports AXL and HGFR kinase inhibitors

AstraZeneca reports results from phase III trial of selumetinib in uveal melanoma

Novel mechanism of cone protection by rod-derived cone viability factor identified

Therabron Therapeutics updates on phase IIa trial of CG-100 in bronchopulmonary dysplasia

Nippon Kayaku's infliximab biosimilar approved for new indication in Japan

Mongersen receives FDA orphan drug designation for pediatric Crohn's disease

AstraZeneca initiates phase IIa study of inhaled interferon-beta for severe asthma

Ablynx and Merck & Co. expand Nanobody collaboration in immuno-oncology

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...